<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of hypertension in asthma and COPD</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of hypertension in asthma and COPD</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of hypertension in asthma and COPD</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven E Weinberger, MD, MACP, FRCP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Umur Hatipoglu, MD, MBA</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen Law, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 17, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The management of hypertension in a patient with asthma or chronic obstructive pulmonary disease (COPD) is a common problem owing to the high prevalence of each condition in the adult population. Indications for treatment of hypertension and use of nonpharmacologic approaches are similar in patients with or without either of these conditions. (See  <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">"Overview of hypertension in adults"</a>.)</p><p class="headingAnchor" id="H3929218520"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Pharmacologic treatment of hypertension in patients with asthma or COPD may be complicated by the asthma-exacerbating effect of some antihypertensives. As an example, beta blockers should be used with great caution or not at all in patients with chronic asthma (but not COPD), acute allergic or exercise-induced bronchospasm, or asthma-COPD overlap syndrome. The angiotensin-converting enzyme (ACE) inhibitors, among the most widely used antihypertensive drugs, are not contraindicated in asthma or COPD, but they can induce a bothersome cough that, although not damaging to the lungs, can be confused with cough due to underlying pulmonary diseases such as asthma and COPD.</p><p class="headingAnchor" id="H2"><span class="h2">Beta blockers</span><span class="headingEndMark"> — </span>Beta blockers can increase airway reactivity and may interfere with the activity of beta-agonists. However, beta blockers are safe for use in most patients with COPD, but less so in patients with asthma.</p><p class="headingAnchor" id="H1955130861"><span class="h3">COPD</span><span class="headingEndMark"> — </span>Beta blockers, particularly beta-1 selective beta blockers  (<a class="graphic graphic_table graphicRef82571" href="/z/d/graphic/82571.html" rel="external">table 1</a>), appear to be safe in most patients with COPD.</p><p>In some observational studies of patients with COPD, beta blocker (including beta-1 selective and nonselective) use was associated with a reduction in mortality and exacerbations of respiratory symptoms [<a href="#rid1">1,2</a>]. In addition, in a meta-analysis including 10 trials of patients with COPD, short-term selective beta-blocker therapy did not change baseline forced expiratory volume in the first second (FEV1) or increase respiratory symptoms [<a href="#rid3">3</a>].</p><p>However, in a subsequent trial including patients with moderate to severe COPD and no primary cardiovascular indication for beta blockers, <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> increased the risk of hospitalization for COPD exacerbations (HR 1.91, 95% CI 1.29-2.83), although the overall rate of COPD exacerbations was not increased [<a href="#rid4">4</a>]. However, in the Rotterdam Study, an observational study including over 1300 participants with COPD, cardioselective beta blockers were associated with a reduced risk of COPD exacerbations only among those who had a cardiovascular indication for use of a beta blocker, but not in those without a cardiovascular indication [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/1437.html" rel="external">"Management of the patient with COPD and cardiovascular disease", section on 'Effect of cardioselective beta blockers on lung function'</a>.)</p><p class="headingAnchor" id="H4286594180"><span class="h3">Asthma</span><span class="headingEndMark"> — </span>In patients with asthma, beta blockers can cause increased bronchial obstruction and airway reactivity, as well as resistance to the effects of inhaled or oral beta receptor agonists (such as <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> or <a class="drug drug_general" data-topicid="9977" href="/z/d/drug information/9977.html" rel="external">terbutaline</a>) [<a href="#rid6">6-8</a>]. Even topical ophthalmic administration of nonselective beta blockers for the treatment of glaucoma has led to asthmatic exacerbations [<a href="#rid9">9</a>]. Although the precise mechanism of beta blocker-induced bronchoconstriction is unknown, parasympathetic pathways of airway control may be involved since the anticholinergic drug oxitropium bromide can inhibit the effect of inhaled <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> [<a href="#rid10">10</a>].</p><p>Although beta-1 selective blockers are safer than nonselective beta blockers  (<a class="graphic graphic_table graphicRef82571" href="/z/d/graphic/82571.html" rel="external">table 1</a>), they should still be used with caution in patients with asthma, particularly in those with severe obstruction or markedly reduced pulmonary function at baseline [<a href="#rid11">11</a>]. As an example, in a meta-analysis of 32 randomized trials including over 1300 patients with asthma, nonselective beta blockers caused a greater reduction in FEV1 compared with beta-1 selective beta blockers (by 10 versus 7 percent), and also attenuated the response to inhaled beta agonists compared with beta-1 selective blockers (by 20 versus 10 percent) [<a href="#rid6">6</a>]. However, one in eight patients on beta-1 selective blockers had a 20 percent or larger decrease in FEV1.</p><p class="headingAnchor" id="H3"><span class="h2">ACE inhibitors</span><span class="headingEndMark"> — </span>ACE inhibitors are not first-line therapy in patients with COPD or asthma. They increase the likelihood of cough (which may be confused with an exacerbation of COPD or asthma) and, in patients with asthma, they may worsen airflow obstruction (although this is uncommon). However, their use is not contraindicated in such patients.</p><p>The most common side effect of therapy with angiotensin-converting enzyme (ACE) inhibitors is cough (typically described as dry, irritative, and persistent, but rarely productive), which develops in 3 to 20 percent of patients [<a href="#rid12">12</a>]. When this cough develops in a patient with either asthma or COPD, it can be confused with an increase in symptoms related to underlying airway disease. There are conflicting data on whether patients with underlying asthma are more likely than non-asthmatics to develop cough after ACE inhibition [<a href="#rid12">12,13</a>].</p><p>There is no evidence of adverse effects of ACE inhibitors on the course of COPD [<a href="#rid14">14</a>]. However, in asthmatic patients, some cases of worsening asthma with ACE inhibitors have been described. In one study examining adverse respiratory effects to ACE inhibitors, reactions diagnosed as asthma, bronchospasm, or dyspnea were reported at one-tenth the frequency of cough, with several cases of bronchospasm occurring in patients with known asthma [<a href="#rid15">15</a>]. In addition, the possibility that ACE inhibitor cough may represent an asthma equivalent has been suggested by the demonstration of bronchial hyperresponsiveness in some, but not all, affected patients [<a href="#rid16">16,17</a>]. (See  <a class="medical medical_review" href="/z/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers", section on 'Cough'</a>.)</p><p>An alternative, when it is desirable to block the renin-angiotensin system, is administration of an angiotensin II receptor blocker. (See  <a class="medical medical_review" href="/z/d/html/3815.html" rel="external">"Renin-angiotensin system inhibition in the treatment of hypertension"</a> and <a class="local">'Angiotensin receptor blockers'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h2">Angiotensin receptor blockers</span><span class="headingEndMark"> — </span>Angiotensin II receptor blockers (ARBs) do not appear to induce cough, and may be used safely in patients with asthma or chronic obstructive pulmonary disease (COPD). In one small trial including hypertensive patients with asthma, there was no increase in cough or bronchial hyperreactivity with an ARB, and it was as well tolerated as calcium channel blockers [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Diuretics</span><span class="headingEndMark"> — </span>Thiazide diuretics are generally safe to use among patients with chronic obstructive pulmonary disease (COPD) [<a href="#rid19">19</a>].</p><p>However, there may be potential issues related to metabolic alkalosis and, among those also using beta agonists or glucocorticoids, hypokalemia:</p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with COPD and chronic hypercapnia, diuretics can also induce a metabolic alkalosis, which can suppress the ventilatory drive and potentially exacerbate hypoxemia [<a href="#rid20">20,21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inhaled beta agonists can drive potassium into the cells, acutely lowering the plasma potassium concentration by as much as 0.5 to 1 mEq/L [<a href="#rid22">22</a>]. Glucocorticoids may lower serum potassium by mildly enhancing urinary potassium excretion [<a href="#rid22">22,23</a>]. Thiazide diuretics also reduce the serum potassium, and therefore concomitant use of these agents with beta agonists or glucocorticoids can exacerbate hypokalemia [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/2341.html" rel="external">"Causes of hypokalemia in adults"</a>.)</p><p></p><p>Thus, it is safest to administer only low thiazide doses (eg, 12.5 to 25 mg of <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">hydrochlorothiazide</a> once daily) to nonedematous hypertensive patients with asthma or COPD. Low-dose therapy may be effective and less likely to produce unwanted side effects such as metabolic alkalosis and hypokalemia. (See  <a class="medical medical_review" href="/z/d/html/3860.html" rel="external">"Use of thiazide diuretics in patients with primary (essential) hypertension"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Calcium channel blockers</span><span class="headingEndMark"> — </span>The calcium channel blockers (especially those of the dihydropyridine group, such as <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> and <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">nicardipine</a>) are excellent agents for the treatment of hypertension in asthma [<a href="#rid21">21,24</a>]. (See  <a class="medical medical_review" href="/z/d/html/3832.html" rel="external">"Major side effects and safety of calcium channel blockers"</a>.)</p><p>In addition to effectively lowering the blood pressure, calcium channel blockers also have the theoretical advantages of opposing muscle contraction in tracheobronchial smooth muscle, inhibiting mast cell degranulation, and possibly reinforcing the bronchodilator effect of beta agonists. <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">Nifedipine</a>, for example, can antagonize the bronchoconstricting effects of antigen, histamine, or cold air challenge [<a href="#rid25">25</a>]. Although some studies have shown a mild improvement in airway function [<a href="#rid25">25</a>], most studies have demonstrated no effect of calcium antagonists on asthma [<a href="#rid26">26,27</a>] .</p><p class="headingAnchor" id="H7"><span class="h2">Sympathetic blockers</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">Clonidine</a> and other alpha-2 receptor agonists (<a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">methyldopa</a>, guanabenz) should be used with caution in asthmatics. Oral doses of these agents do not change baseline air flow in asthmatics, but they do increase bronchial reactivity to inhaled histamine [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Other</span><span class="headingEndMark"> — </span>Little specific information is available for the remaining antihypertensive agents, such as <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>. However, if asthma occurs with these or other drugs, one should always consider the possibility that the tartrazine dye within the drug preparation may be the culprit.</p><p class="headingAnchor" id="H571166237"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109601.html" rel="external">"Society guideline links: Hypertension in adults"</a>.)</p><p class="headingAnchor" id="H13075016"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Indications for treatment of hypertension and use of nonpharmacologic approaches are similar in patients with or without asthma or chronic obstructive pulmonary disease (COPD). The management of hypertension in a patient with either of these conditions may be made difficult by the asthma-exacerbating effect of some antihypertensive drugs. (See <a class="local">'Introduction'</a> above and <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta blockers</strong> – Beta blockers can cause increased bronchial obstruction and airway reactivity, as well as resistance to the effects of inhaled or oral beta receptor agonists (such as <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> or <a class="drug drug_general" data-topicid="9977" href="/z/d/drug information/9977.html" rel="external">terbutaline</a>) in patients with asthma but not COPD. Although the clinical effects of more beta-1-selective beta blockers on pulmonary function appear to be less severe, even beta-1-selective agents should be used with caution in asthmatic patients with severe obstruction or markedly reduced baseline pulmonary function  (<a class="graphic graphic_table graphicRef82571" href="/z/d/graphic/82571.html" rel="external">table 1</a>). (See <a class="local">'Beta blockers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACE inhibitors and angiotensin receptor blockers</strong> – Angiotensin-converting enzyme (ACE) inhibitors are not first-line therapy in patients with COPD or asthma. They increase the likelihood of cough (which may be confused with an exacerbation of COPD or asthma) and, in patients with asthma, they may worsen airflow obstruction (although this is uncommon). However, their use is not contraindicated in such patients. An alternative, when it is desirable to block the renin-angiotensin system, is administration of an angiotensin II receptor blocker. (See <a class="local">'ACE inhibitors'</a> above and <a class="local">'Angiotensin receptor blockers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diuretics</strong> – Diuretics can be effectively used in asthmatics but may cause serious hypokalemia if used concurrently with inhaled beta-2 receptor agonists, which drive potassium into the cells, and oral corticosteroids, which enhance urinary potassium excretion. In addition, diuretic-induced metabolic alkalosis can suppress ventilatory drive, potentially exacerbating the degree of hypoxemia. It is safest to administer only low thiazide doses (12.5 to 25 mg of <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">hydrochlorothiazide</a> once daily) to nonedematous hypertensive patients with asthma or COPD. (See <a class="local">'Diuretics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcium channel blockers</strong> – The calcium channel blockers (especially those of the dihydropyridine group, such as <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> and <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">nicardipine</a>) are excellent agents for the treatment of hypertension in asthma. In addition to effectively lowering the blood pressure, they also have the theoretical advantages of opposing muscle contraction in tracheobronchial smooth muscle, inhibiting mast cell degranulation, and possibly reinforcing the bronchodilator effect of beta agonists. (See <a class="local">'Calcium channel blockers'</a> above.)</p><p></p><p class="headingAnchor" id="H2210677404"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Norman Kaplan, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170:880.</a></li><li><a class="nounderline abstract_t">Bhatt SP, Wells JM, Kinney GL, et al. β-Blockers are associated with a reduction in COPD exacerbations. Thorax 2016; 71:8.</a></li><li><a class="nounderline abstract_t">Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002; 137:715.</a></li><li><a class="nounderline abstract_t">Dransfield MT, Voelker H, Bhatt SP, et al. Metoprolol for the Prevention of Acute Exacerbations of COPD. N Engl J Med 2019; 381:2304.</a></li><li><a class="nounderline abstract_t">Karimi L, Lahousse L, De Nocker P, et al. Effect of β-blockers on the risk of COPD exacerbations according to indication of use: the Rotterdam Study. ERJ Open Res 2021; 7.</a></li><li><a class="nounderline abstract_t">Morales DR, Jackson C, Lipworth BJ, et al. Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. Chest 2014; 145:779.</a></li><li><a class="nounderline abstract_t">Benson MK, Berrill WT, Cruickshank JM, Sterling GS. A comparison of four beta-adrenoceptor antagonists in patients with asthma. Br J Clin Pharmacol 1978; 5:415.</a></li><li><a class="nounderline abstract_t">Christiansen SC, Zuraw BL. Treatment of Hypertension in Patients with Asthma. N Engl J Med 2019; 381:1046.</a></li><li><a class="nounderline abstract_t">Fraunfelder FT, Barker AF. Respiratory effects of timolol. N Engl J Med 1984; 311:1441.</a></li><li><a class="nounderline abstract_t">Ind PW, Dixon CM, Fuller RW, Barnes PJ. Anticholinergic blockade of beta-blocker-induced bronchoconstriction. Am Rev Respir Dis 1989; 139:1390.</a></li><li><a class="nounderline abstract_t">Finks SW, Rumbak MJ, Self TH. Treating Hypertension in Chronic Obstructive Pulmonary Disease. N Engl J Med 2020; 382:353.</a></li><li><a class="nounderline abstract_t">Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117:234.</a></li><li><a class="nounderline abstract_t">Kaufman J, Casanova JE, Riendl P, Schlueter DP. Bronchial hyperreactivity and cough due to angiotensin-converting enzyme inhibitors. Chest 1989; 95:544.</a></li><li><a class="nounderline abstract_t">Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47:2554.</a></li><li><a class="nounderline abstract_t">Lunde H, Hedner T, Samuelsson O, et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1994; 308:18.</a></li><li><a class="nounderline abstract_t">Bucknall CE, Neilly JB, Carter R, et al. Bronchial hyperreactivity in patients who cough after receiving angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed) 1988; 296:86.</a></li><li><a class="nounderline abstract_t">Boulet LP, Milot J, Lampron N, Lacourcière Y. Pulmonary function and airway responsiveness during long-term therapy with captopril. JAMA 1989; 261:413.</a></li><li><a class="nounderline abstract_t">Tanaka H, Teramoto S, Oashi K, et al. Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. Circulation 2001; 104:281.</a></li><li><a class="nounderline abstract_t">Herrin MA, Feemster LC, Crothers K, et al. Combination antihypertensive therapy among patients with COPD. Chest 2013; 143:1312.</a></li><li><a class="nounderline abstract_t">Bear R, Goldstein M, Phillipson E, et al. Effect of metabolic alkalosis on respiratory function in patients with chronic obstructive lung disease. Can Med Assoc J 1977; 117:900.</a></li><li><a class="nounderline abstract_t">Cazzola M, Noschese P, D'Amato G, Matera MG. The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction. Chest 2002; 121:230.</a></li><li><a class="nounderline abstract_t">Lipworth BJ, McDevitt DG, Struthers AD. Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol. Am J Med 1989; 86:653.</a></li><li><a class="nounderline abstract_t">Wong CS, Pavord ID, Williams J, et al. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990; 336:1396.</a></li><li><a class="nounderline abstract_t">Barnes PJ. Clinical studies with calcium antagonists in asthma. Br J Clin Pharmacol 1985; 20 Suppl 2:289S.</a></li><li><a class="nounderline abstract_t">Schwartzstein RS, Fanta CH. Orally administered nifedipine in chronic stable asthma. Comparison with an orally administered sympathomimetic. Am Rev Respir Dis 1986; 134:262.</a></li><li><a class="nounderline abstract_t">Ann Twiss M, Harman E, Chesrown S, Hendeles L. Efficacy of calcium channel blockers as maintenance therapy for asthma. Br J Clin Pharmacol 2002; 53:243.</a></li><li><a class="nounderline abstract_t">Patakas D, Maniki E, Tsara V, Dascalopoulou E. Nifedipine treatment of patients with bronchial asthma. J Allergy Clin Immunol 1987; 79:959.</a></li><li><a class="nounderline abstract_t">Dinh Xuan AT, Matran R, Regnard J, et al. Comparative effects of rilmenidine and clonidine on bronchial responses to histamine in asthmatic subjects. Br J Clin Pharmacol 1988; 26:703.</a></li></ol></div><div id="topicVersionRevision">Topic 3831 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20498416" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26283710" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : β-Blockers are associated with a reduction in COPD exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12416945" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31633896" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Metoprolol for the Prevention of Acute Exacerbations of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34195251" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect ofβ-blockers on the risk of COPD exacerbations according to indication of use: the Rotterdam Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24202435" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adverse respiratory effect of acuteβ-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26371" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A comparison of four beta-adrenoceptor antagonists in patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31509675" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Treatment of Hypertension in Patients with Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6493304" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Respiratory effects of timolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2658700" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Anticholinergic blockade of beta-blocker-induced bronchoconstriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31971680" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Treating Hypertension in Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1616218" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2537709" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Bronchial hyperreactivity and cough due to angiotensin-converting enzyme inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16781387" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8298346" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2827838" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Bronchial hyperreactivity in patients who cough after receiving angiotensin converting enzyme inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2642559" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pulmonary function and airway responsiveness during long-term therapy with captopril.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11457745" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23287970" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Combination antihypertensive therapy among patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21028" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effect of metabolic alkalosis on respiratory function in patients with chronic obstructive lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11796456" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2729315" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1978872" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3902071" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical studies with calcium antagonists in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3740651" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Orally administered nifedipine in chronic stable asthma. Comparison with an orally administered sympathomimetic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11874387" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy of calcium channel blockers as maintenance therapy for asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3294978" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Nifedipine treatment of patients with bronchial asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2907408" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comparative effects of rilmenidine and clonidine on bronchial responses to histamine in asthmatic subjects.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
